EU opens rare excessive pricing investigation
Credit: iStock/josemoraes
The European Commission has opened a formal investigation into Aspen following concerns that the drugmaker has unjustifiably increased the price of several anti-cancer medications, marking the enforcer’s first excessive pricing case in the pharmaceutical sector.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now